CCR1, BOB, Bonzo, CCR5 or CXCR4 (ref. 2) were infected with pseudotyped viruses (50 ng p24 per infection, 5×10^4 cells per well in 24-well plates). 3T3.CD4 cells that stably express the different chemokine receptors² were similarly infected. 3T3.CD4 cells expressing the new receptors were prepared by retroviral transduction with pMX.Bonzo and pMX.BOB. After 3 days, cells were resuspended in 120 μ l of luciferase lysis buffer (Promega). The luciferase activity in 20 μ l lysate was assayed in a Wallac Microbeta 1450 Counter using commercially available reagents (Promega).

Northern blots. Polyadenylated RNA was prepared from various human cell lines with the Micro-Fast Track kit (Invitrogen). Samples (5 μ g RNA) were electrophoresed through a 1% agarose-formaldehyde gel and transferred to a GeneScreen nitrocellulose membrane. Multiple-tissue northern blots I and II, purchased from Clontech, contain $\sim 2 \mu$ g poly(A)⁺ RNA from each tissue. Integrity of blots was assayed by GAPDH probing. Full-length cDNAs of BOB and Bonzo were labelled with ³²P by using a Random Primed DNA-labelling kit (Boehringer-Mannheim) and used to probe northern blots.

Lymphocyte purification and RT-PCR. Monocytes were purified from buffy coats using a 46% Percoll gradient. To purify T- and B-cell subsets, PBMC were stained with phycoerythrin-conjugated anti-CD3 or anti-CD19 antibodies (Becton-Dickinson) and sorted using FACS (Coulter). Total RNA was isolated using RNazol reagent (Cinna/Biotech), treated with RNase-free DNase, and 0.5 μ g was taken for cDNA synthesis using Superscript II RNase H reverse transcriptase and random hexamer primers (Gibco-BRL); one-twentieth of this reaction was used as a template for PCR amplification with *Taq* DNA polymerase. BOB primers used for RT-PCR: upstream (from ATG) 5'-CATCTGCTCTTTGGTGATG; downstream (550 bp from ATG), 5'-GTATGGCTTATCATCAATCAGC, amplifies ~ 600 bp of transcript; Bonzo primers were: upstream (from 270 bp downstream of ATG), 5'-CAGGCATC-CATGAATGGGTGT, and downstream (from the stop codon), 5'-CAAGGCC-TATACTGGAACATGCTG, amplifies ~ 750 bp of transcript. The PCR reaction was run for 30 cycles at 94 °C for 40 s, 58 °C for 40 s, and 72 °C for 1 min. To exclude contamination of genomic DNA, control cDNA reactions in which reverse transcriptase was omitted were prepared in parallel. These were uniformly negative.

Received 27 May; accepted 23 June 1997.

- Feng, Y., Broder, C. C., Kennedy, P. E. & Berger, E. A. HIV-1 entry cofactor: functional cDNA cloning of a seven-transmembrane, G protein-coupled receptor. *Science* **272**, 872–877 (1996).
- Deng, H. *et al.* Identification of a major co-receptor for primary isolates of HIV-1. *Nature* **381**, 661–666 (1996).
- Alkhatib, G. *et al.* CC CKR5: a RANTES, MIP-1 α , MIP-1 β receptor as a fusion cofactor for macrophage-tropic HIV-1. *Science* **272**, 1955–1958 (1996).
- Dragic, T. *et al.* HIV-1 entry into CD4⁺ cells is mediated by the chemokine receptor CC-CKR-5. *Nature* **381**, 667–673 (1996).
- Doranz, B. J. *et al.* A dual-tropic primary HIV-1 isolate that uses fusin and the β -chemokine receptors CKR-5, CKR-3 and CKR-2b as fusion cofactors. *Cell* **85**, 1149–1158 (1996).
- Choe, H. *et al.* The beta-chemokine receptors CCR3 and CCR5 facilitate infection by primary HIV-1 isolates. *Cell* **85**, 1135–1148 (1996).
- Chen, Z., Zhou, P., Ho, D. D., Landau, N. R. & Marx, P. A. Genetically divergent strains of simian immunodeficiency virus use CCR5 as a coreceptor for entry. *J. Virol.* **71**, 2705–2715 (1997).
- Marcon, L. *et al.* Utilization of C-C chemokine receptor 5 by the envelope glycoproteins of a pathogenic simian immunodeficiency virus, SIVmac239. *J. Virol.* **71**, 2522–2527 (1997).
- Edinger, A. L. *et al.* Differential utilization of CCR5 by macrophage and T cell tropic simian immunodeficiency virus strains. *Proc. Natl Acad. Sci. USA* **94**, 4005–4010 (1997).
- Hill, C. M. *et al.* Envelope glycoproteins from HIV-1, HIV-2, and SIV can use human CCR5 as a coreceptor for viral entry and make direct CD4-dependent interactions with this chemokine receptor. *J. Virol.* (in the press).
- Marthas, M. L. *et al.* Rhesus macaques inoculated with molecularly cloned simian immunodeficiency virus. *J. Med. Primatol.* **18**, 311–319 (1989).
- Fukasawa, M. *et al.* Sequence of simian immunodeficiency virus from African green monkey, a new member of the HIV/SIV group. *Nature* **333**, 457–461 (1988).
- Clapham, P. R., Blanc, D. & Weiss, R. A. Specific cell surface requirements for the infection of CD4-positive cells by human immunodeficiency virus types 1 and 2 and by simian immunodeficiency virus. *Virology* **181**, 703–715 (1991).
- Stefano, K. A. *et al.* Replication of a macrophage-tropic strain of human immunodeficiency virus type 1 (HIV-1) in a hybrid cell line, CEM $\times$ 174, suggests that cellular accessory molecules are required for HIV-1 entry. *J. Virol.* **67**, 6707–6715 (1993).
- Heiber, M. *et al.* A novel human gene encoding a G-protein-coupled receptor (GPR15) is located on chromosome 3. *Genomics* **32**, 462–465 (1996).
- He, J. *et al.* CCR3 and CCR5 are co-receptors for HIV-1 infection of microglia. *Nature* **385**, 645–649 (1997).
- Fauci, A. S. Host factors and the pathogenesis of HIV-induced disease. *Nature* **384**, 529–534 (1996).
- Desrosiers, R. C. The simian immunodeficiency viruses. *Annu. Rev. Immunol.* **8**, 557–578 (1990).
- Kestler, H. *et al.* Induction of AIDS in rhesus monkeys by molecularly cloned simian immunodeficiency virus. *Science* **248**, 1109–1112 (1990).
- Theodorou, I., Meyer, L., Magierowska, M., Katlama, C. & Rouzioux, C. HIV-1 infection in an individual homozygous for CCR5 delta 32. *Seroco Study Group. Lancet* **349**, 1219–1220 (1997).
- Biti, R. *et al.* HIV-1 infection in an individual homozygous for the CCR5 deletion allele. *Nature Med.* **3**, 252–253 (1997).
- O'Brien, T. R. *et al.* HIV-1 infection in a man homozygous for CCR5 delta 32. *Lancet* **349**, 1219 (1997).
- Kitamura, T. *et al.* Efficient screening of retroviral cDNA expression libraries. *Proc. Natl Acad. Sci. USA* **92**, 9146–9150 (1995).
- Landau, N. R., Page, K. A. & Littman, D. R. Pseudotyping with human T-cell leukemia virus type I broadens the human immunodeficiency virus host range. *J. Virol.* **65**, 162–169 (1991).
- Westervelt, P., Gendelman, H. E. & Ratner, L. Identification of a determinant within the human immunodeficiency virus 1 surface envelope glycoprotein critical for productive infection of primary monocytes. *Proc. Natl Acad. Sci. USA* **88**, 3097–3101 (1991).
- Hwang, S. S., Boyle, T. J., Lyerly, H. K. & Cullen, B. R. Identification of envelope V3 loop as the major determinant of CD4 neutralization sensitivity of HIV-1. *Science* **257**, 535–537 (1992).
- Gao, F. *et al.* Molecular cloning and analysis of functional envelope genes from human immunodeficiency virus type 1 sequence subtypes A through G. (The WHO and NIAID Networks for HIV Isolation and Characterization.) *J. Virol.* **70**, 1651–1657 (1996).
- Barnett, S. W., Quiroga, M., Werner, A., Dina, D. & Levy, J. A. Distinguishing features of an infectious molecular clone of the highly divergent and noncytopathic human immunodeficiency virus type 2 UC1 strain. *J. Virol.* **67**, 1006–1014 (1993).
- Kong, L. I. *et al.* West African HIV-2-related human retrovirus with attenuated cytopathicity. *Science* **240**, 1525–1529 (1988).
- Gao, F. *et al.* Human infection by genetically diverse SIVSM-related HIV-2 in west Africa. *Nature* **358**, 495–499 (1992).
- Liao, S. *et al.* *J. Exp. Med.* **185**, 2015–2023 (1997).

Acknowledgements. We thank T. Kitamura for the pMX retroviral library; R. Sutton for construction of HIV-puro; C. Mackay for the monoclonal antibody against CCR5; P. Cresswell for 174 and CEM cell lines, B. Hahn for virus isolates; M. Emerman for pL-VSV-G; C. Weiss for HIV-2 Env vectors; G. Pare for technical assistance; W. Ellmeier for help with northern blots; and C. Davis, C. M. Hill and M. Vlodavich for comments on the manuscript. This work was supported by grants from the NIH and by postdoctoral fellowships from the Aaron Diamond Foundation (H.-K.D.) and the Damon Runyon-Walter Winchell Foundation (V.N.K.). D.R.L. is an investigator of the Howard Hughes Medical Institute.

Correspondence and requests for materials should be addressed to D.R.L. (e-mail: littman@saturn.med.nyu.edu). Genbank sequence accession numbers are: human Bonzo, AF007545; BOB (African green monkey), AF007856; BOB (pigtailed macaque), AF007857; Bonzo (pigtailed macaque), AF007858; Bonzo (African green monkey), AF007859.

X-linked IAP is a direct inhibitor of cell-death proteases

Quinn L. Deveraux*, Ryosuke Takahashi*, Guy S. Salvesen & John C. Reed

The Burnham Institute, Program on Apoptosis and Cell Death Research, 10901 North Torrey Pines Road, La Jolla, California 92037, USA

* These authors contributed equally to this work.

The *inhibitor-of-apoptosis (IAP)* family of genes has an evolutionarily conserved role in regulating programmed cell death in animals ranging from insects to humans^{1–6}. Ectopic expression of human IAP proteins can suppress cell death induced by a variety of stimuli, but the mechanism of this inhibition was previously unknown. Here we show that human X-chromosome-linked IAP directly inhibits at least two members of the caspase family of cell-death proteases, caspase-3 and caspase-7. As the caspases are highly conserved throughout the animal kingdom and are the principal effectors of apoptosis⁷, our findings suggest how IAPs might inhibit cell death, providing evidence for a mechanism of action for these mammalian cell-death suppressors.

For our initial investigation of human X-chromosome-linked IAP (XIAP; hIAP; MIHA), we used recombinant XIAP protein and a cell-free system in which cytochrome *c* was added to cytosolic extracts. When added to normal cytosol, cytochrome *c* initiates an apoptotic programme which includes proteolytic processing and activation of certain caspases, and apoptotic-like destruction of exogenously added nuclei⁸. Release of cytochrome *c* from mitochondria into the cytosol appears to be commonly associated with apoptosis^{8,9}.

Purified nuclei mostly remained intact in the cytosol from controls. In contrast, adding cytochrome *c* caused apoptotic-like destruction of nearly all nuclei (Fig. 1A). Addition of cytochrome *c* directly to nuclei without cytosol had no effect, demonstrating the requirement for cytosolic factors (results not shown)⁸. Recombinant XIAP (rXIAP) added simultaneously with cytochrome *c* severely inhibited nuclear destruction (Fig. 1A). An equivalent

amount of added Bcl-2 protein had no protective effect.

In addition to nuclear destruction, XIAP also inhibited cytochrome-*c*-induced caspase activation. Two important proteolytic activities associated with caspases can be measured by assaying the cleavage of peptide substrates containing the sequences DEVD and YVAD: the former are recognized by most caspases and the latter by the ICE (caspase-1) subfamily (reviewed in ref. 10). Addition of cytochrome *c* to extracts prepared from human 293 epithelial cells caused a rapid accumulation of DEVD-specific protease activity (Fig. 1B) but not of YVAD-specific cleavage (results not shown). The rXIAP protein markedly reduced cytochrome-*c*-induced generation of DEVD-cleaving activity in these extracts, whereas many control proteins had little or no effect even at ≥ 10 -fold molar excess over rXIAP (Fig. 1B). Results were similar when DEVD-specific hydrolysis was measured for cytosol from Jurkat T-cells, indicating that these findings are probably not unique to a single cell line (Fig. 1B). Furthermore, in cytosolic extracts prepared from 293T cells two days after transient transfection with either pcDNA3-XIAP or pcDNA3 control plasmid, cytochrome-*c*-induced activation of DEVD-cleaving proteases *in vitro* was reduced by > 50% in the XIAP-overexpressing extracts compared to control extracts (not shown). Thus, both exogenously added rXIAP and endogenously produced XIAP inhibit cytochrome-*c*-induced caspase activation *in vitro*.

Addition of cytochrome *c* to cytosolic extracts causes proteolytic processing of caspase-3 (CPP32; Yama; apopain) from its ~32K zymogen precursor into active large and small subunits—a result we confirmed by immunoblotting using a rabbit antiserum specific for the zymogen and large subunit of this protease (Fig. 1C). In contrast, addition of rXIAP protein markedly inhibited cytochrome-*c*-induced cleavage of the caspase-3 zymogen (Fig. 1C). Equivalent concentrations of several control proteins (glutathione-S-transferase (GST), GST-Bcl-2, GST-Bax, GST-CD40) had no effect on caspase-3 processing (result not shown).

As an alternative way to induce apoptosis in these extracts, we added recombinant, active caspase-8 (FLICE; Mach; Mch5), a protease that associates with Fas and TNF-R1 receptor complexes and functions as an upstream initiator of proteolytic cascades that lead to caspase-3 activation and apoptosis^{11–14}. Caspase-8 stimulated cleavage of caspase-3, yielding large-subunit bands characteristic of protease activation (Fig. 1C). In the presence of XIAP, caspase-8 induced a partially processed form of caspase-3, presumably by cleavage between the large and small subunits without the subsequent removal of the N-terminal peptide 'prodomain'¹⁵. XIAP thus did not prevent the initial cleavage of caspase-3 induced (perhaps directly) by caspase-8, but did inhibit the subsequent processing to the mature large subunit. XIAP also inhibited caspase-8-induced destruction of nuclei and the accumulation of DEVD-specific protease in extracts (not shown), indicating that it interferes with a protease(s) downstream of caspase-8.

As XIAP prevents the completion of caspase-3 processing in extracts treated with caspase-8, XIAP might directly inhibit this protease, given that removal of the N-terminal prodomain of caspase-3 occurs by autocatalysis^{15,16}. We therefore tested the effect of rXIAP on the activity of several purified and active recombinant caspases *in vitro*. Purified GST-XIAP inhibited >95% of DEVD-peptide cleavage by caspase-3 and by the closely related caspase-7 (LAP3/Mch3) when added at a ~10-fold molar excess, but did not affect substrate cleavage by caspases 8, 6 (Mch2) or 1, even at 50-fold molar excess (Fig. 2a). Even a 2-fold molar excess of XIAP was sufficient to inhibit >70% of caspase-3 and ~100% of caspase-7 activity when assayed at high enzyme concentrations (0.5–0.7 μ M) and with XIAP added before 100 μ M DEVD-pNA substrate. A GST-fusion protein containing only the three BIR (baculovirus IAP repeat) domains of XIAP (residues 1–336) also potently inhibited caspase-3 and caspase-7 *in vitro*, whereas a GST fusion containing the RING domain (residues 337–497), as well as several control

Figure 1 XIAP inhibits cytochrome-*c*-induced processing of caspase-3 and destruction of nuclei in cytosolic extracts. **A**, Isolated nuclei were added to cytosolic extracts, followed by 10 μ M cytochrome *c* and 1 mM dATP, with or without GST-XIAP (0.4 μ M) or GST-Bcl-2 (0.4 μ M), and the percentage of nuclei with apoptotic features was determined (data representative of 2 of 2 experiments). **B**, Cytosolic extracts from 293 or Jurkat cells were used as a control (a) or were treated with 1 μ M cytochrome *c* and 1 mM dATP alone (b), or with ~0.2 μ M GST-XIAP (c). Controls (grey lines) consisted of addition of ~10x more (~2 μ M) control GST-fusion proteins, including GST-Bcl-2 (d), GST-Bax (e), GST-NM23 (f) and GST-CD40 cytosolic domain (g), or addition of 5 μ M His₆-S5a protein (h). DEVD-pNA hydrolysis was then measured at various times (data representative of several experiments performed with independent GST-XIAP preparations). **C**, Immunoblot analysis for caspase-3 was performed using cytosolic extracts (50 μ g per lane) before or at 0.5 and 1.0 h after adding either cytochrome *c* and dATP or active caspase-8 proteases (~1 μ g), with (+) or without (–) ~0.2 μ M GST-XIAP (30- μ l reaction volumes). The positions are noted for the pro-enzyme, partially processed caspase-3 (large subunit + prodomain) and the large subunit forms of fully processed caspase-3. The blot was also probed with anti-XIAP antiserum (lower panel).

GST-fusion proteins, had no significant effect (not shown). The inhibition of caspase-3 and caspase-7 by XIAP was concentration-dependent (Fig. 2b,c). Based upon progress curve analysis, XIAP demonstrated tight, reversible binding to caspase-3 and caspase-7 with inhibition constants of ~ 0.7 and ~ 0.2 nM, respectively. These values compare favourably with viral inhibitors of caspases (cowpox CrmA: 0.01–0.95 nM; baculovirus p35: 1.0 nM for their target caspases)^{17,18}.

Besides inhibiting the proteolytic activity of caspase-3 and caspase-7, XIAP also bound directly to these proteases *in vitro*. For example, mixing purified GST–XIAP protein or GST–CD40 (negative control) immobilized on glutathione–Sephacrose with purified recombinant caspases revealed specific binding of XIAP to caspase-3 and caspase-7 but not to caspases 1, 6 or 8 (Fig. 2d, and data not shown). Specific binding to caspase-3 and caspase-7 was also observed when *in vitro* translated ³⁵S-labelled Myc-tagged XIAP was tested for binding to His₆-tagged active proteases immobilized

on Ni resin (not shown). XIAP, however, did not bind efficiently to the unprocessed pro-enzymes, based on similar experiments in which immobilized GST–XIAP was assayed for binding to unprocessed caspase-3 and caspase-7 in cytosolic extracts (Fig. 2e,f). In contrast, after treatment of the same extracts with cytochrome c, processed caspase-3 and caspase-7 then bound to immobilized GST–XIAP but not GST–CD40. The partially processed caspase-3 seen in extracts treated with the combination of caspase-8 and rXIAP (Fig. 1C) also bound efficiently to immobilized GST–XIAP (not shown), consistent with the idea that cleavage between the large and small subunit but not removal of the prodomain is required for protease activation. Taken together, these data indicate that XIAP directly binds active caspase-3 and caspase-7, but not the inactive zymogens.

To determine whether XIAP can inhibit processing and activation of caspases in intact cells, we did transient transfection experiments in human 293T cells using overexpression of Bax protein as a

Figure 2 XIAP directly binds and inhibits caspase-3 and caspase-7. **a**, Purified recombinant caspases 1, 3, 6, 7 and 8 (1–10 nM) were incubated with or without up to a 50-fold molar excess of XIAP (10–50 nM range). Data are expressed as per cent inhibition, based on the average ratio of velocities (v_i/v_0) of three independent experiments (mean $\pm$ s.e.) performed in the presence (v_i) or absence (v_0) of GST–XIAP. **b, c**, Representative progress curves are shown for caspase-3 (0.05 nM) and caspase-7 (0.1 nM), respectively, in which XIAP was added at various concentrations (nM) simultaneously with substrate (100 μ M DEVD-AFC). **d**, GST–XIAP or

GST–CD40 on glutathione–Sephacrose were tested for binding to active recombinant proteases by immunoblotting. As a control, purified proteases (0.1 μ g) were run directly in the gel. **e, f**, GST–XIAP or GST–CD40 fusion proteins immobilized on glutathione–Sephacrose were assayed by immunoblotting for binding to caspase-3 (**e**) or caspase-7 (**f**) in untreated ('control') 293 cytosolic extracts or after activation with cytochrome c. As a control, lysates (50 μ g) were run directly in gels. A nonspecific band detected by the caspase-7 antiserum in cell lysates is indicated by a dot to distinguish it from the processed ~ 20 K large subunit.

Figure 3 XIAP inhibits Bax-induced caspase-3 processing and cell death in 293T cells. **a**, The percentage of dead (uptake of propidium iodide) and apoptotic (*hypodiploid DNA content) cells (mean $\pm$ s.e. for 3 determinations) was determined 1 day after transfection of 293T cells with pcDNA3 ('C'), pcDNA3-Bax, pcDNA3-Myc-XIAP, or pcDNA3-Bax and pcDNA3-Myc-XIAP. ZVAD-fmk (50 μ M)

(Bachem) was added immediately after Bax-transfection. Extracts were prepared from transfected cells for either **b**, protease assay (DEVD-AFC cleavage activity; expressed as relative fluorescence units, RFU), or **c**, immunoblot analysis of caspase-3 processing. Different exposure was used for 32K pro- and 17K processed caspase-3.

stimulus for inducing apoptosis and caspase-3 activation. Previously Bax had been shown to induce mitochondrial permeability transition (predicted to cause the release of cytochrome *c*) and processing of caspases 3, 6 and 7 (ref. 19). Transfection of a Bax-encoding plasmid into 293T cells caused an approximately 8–10-fold increase in cell death (as measured by trypan-blue or propidium iodide uptake) about an 8–10-fold increase in apoptosis (as measured by DNA fragmentation) compared to control transfected cells (Fig. 3a). In contrast, when Bax- and XIAP-encoding plasmids were co-transfected, Bax-mediated cell death and apoptosis were inhibited ($P < 0.01$; *t*-test). Immunoblotting confirmed that the Myc-tagged XIAP protein was expressed in the expected transfected cells and verified that XIAP did not inhibit production of Bax protein (not shown), implying that XIAP blocks an event downstream of Bax. A Myc-tagged version of XIAP containing only the BIR domains was as effective as the full-length protein at suppressing Bax-induced apoptosis, whereas the RING domain of XIAP was inactive (the percentages of apoptotic cells, based on hypodiploid DNA content, were $11 \pm 1\%$ (neo control), $53 \pm 2\%$ (Bax), $15 \pm 0.5\%$ (Bax + XIAP), $18 \pm 1\%$ (Bax + BIRs), $47 \pm 1\%$ (Bax + RING)). The caspase-inhibiting peptide zVAD-fmk also inhibited Bax-induced apoptosis in 293T cells, consistent with a role for caspases in Bax-triggered cell death in these cells.

Extracts prepared from Bax-transfected 293T cells also contained much more caspase activity and processed caspase-3 than did control transfected cells. In contrast, analysis of extracts from cells co-transfected with Bax and XIAP revealed that XIAP markedly inhibited Bax-induced generation of caspase activity (Fig. 3b) and caspase-3 processing (Fig. 3c). This suppression of caspase-3 processing in cells (Fig. 3c) and cytosolic extracts *in vitro* (Fig. 1c) implies that XIAP either blocks the activity of caspases upstream of caspase-3 or that it prevents caspase-3-mediated processing of procaspase-3.

We have described, to our knowledge for the first time, a mechanism of action for an IAP-family protein: namely, inhibition of active cell-death proteases. Although viral proteins such as CrmA and p35 bind to and inhibit caspases, XIAP is the first cellular protein identified with these characteristics. The extensive homology shared by IAP-family proteins across evolution (particularly in the BIR domains) suggests that other members of this family of apoptosis-suppressing proteins also inhibit specific caspases. Although apoptosis seems uniformly to require the participation of caspases²⁰, the particular caspases necessary vary according to cell-type and the stimulus triggering cell death^{21,22}. Therefore, the ability of each IAP family member to inhibit apoptosis may also vary, depending on the cell and the stimulus involved. XIAP, for instance, may be an effective inhibitor only of apoptotic stimuli that depend on caspase-3 and/or caspase-7. Further experiments will determine in which cell-types and under which apoptosis-stimulating conditions XIAP effectively prevents apoptosis. □

Methods

Expression and purification of proteins. A XIAP-encoding cDNA was obtained by RT-PCR using a first-strand cDNA derived from Jurkat cells as the template and specific primers based upon Genbank accession number U32974 (forward primer, 5'-GGGAATTCATGACTTTTAAACAGTTTGAAGGAT-3'; reverse primer, 5'-CTCTCGAGCATGCCTACTATAGAGTTAGA-3'). The PCR product was digested with *Eco*RI and *Xho*I, followed by ligation into pcDNA3 (Invitrogen) containing an N-terminal Myc tag and into pGEX4T-1 (Pharmacia). Plasmid pGEX4T-1-XIAP was then introduced into an *E. coli* strain BL21(DE3) harbouring the plasmid pT-Trx²³. The GST-XIAP fusion protein was prepared from the soluble fraction upon induction with 0.2 mM IPTG at 30 °C for 3 h, affinity-purified using glutathione-Sepharose, and then dialysed against PBS.

Full-length cDNAs encoding caspases 3, 6 and 7, and a cDNA encoding the catalytic subunits of caspase-8 (Ser 216 → C terminus) were subcloned into

pET vectors (Novagen), expressed in *E. coli* strain BL21(DE3)pLysS as His₆-tagged proteins, and purified as described^{14,16,17}. The preparation of recombinant control proteins, GST-Bcl-2, GST-Bax, GST-CD40 cytosolic domain and His₆-S5a proteasome subunit, has been described^{24–26}.

Enzyme assays. Caspase activity was assayed by release of 7-amino-4-trifluoromethyl-coumarin (AFC) or *p*-nitroaniline (pNA) from YVAD- or DEVD-containing synthetic peptides using continuous-reading instruments as described¹⁷. Inhibition rates and equilibria were determined by progress curves in which DEVD-AFC hydrolysis was measured using ~0.1 nM caspases and a range of concentrations of rXIAP (0.1–12 μM). K_i was calculated without any assumption of the inhibitory mechanism, and therefore without adjustment for the 0.1 mM DEVD-AFC substrate concentration¹⁷. The specific activities of the enzymes (k_{cat}/K_m) were estimated using Ac-YVAD-AFC for caspase-1 and Ac-DEVD-AFC for all others, and ranged from $1.3 \times 10^4 \text{ M}^{-1} \text{ s}^{-1}$ for caspase-8 to $1.3 \times 10^6 \text{ M}^{-1} \text{ s}^{-1}$ for caspase-3 (Q. Zhou and G.S.S., manuscript in preparation).

Preparation and induction of the cell-free apoptotic system. Cell extracts were prepared as described⁸, but with several modifications, using 293 embryonic kidney or Jurkat T cells. Cells were washed with ice-cold buffer A (20 mM HEPES (pH 7.5), 10 mM KCl, 1.5 mM MgCl₂, 1 mM EDTA, 1 mM DTT and 0.1 mM PMSF) and suspended in one volume of buffer A. Cells were incubated on ice for 20 min and then disrupted either by passage through a 26-gauge needle 15 times (293 cells) or Dounce-homogenized 15 times in 2 ml buffer using a B-type pestle (Jurkat T-cells). Cell extracts (10–15 mg total protein per ml) were clarified by centrifugation at 16,000g for 30 min and the NaCl concentration increased by 50 mM. For initiating caspase activation, 1 μM horse heart cytochrome *c* (Sigma) and 1 mM dATP were added. Nuclei were prepared from HeLa cells¹⁵ and stained with 0.1 μg μl⁻¹ of acridine orange or ethidium bromide.

Immunoblot analysis. Immunoblotting for caspases was done as described, using 750 mM Tris/12% polyacrylamide gels, after normalizing cell lysates for protein content^{27,28}. Antiserum specific for XIAP was prepared in rabbits using a synthetic peptide NH₂-CDAVSSDRNFPNSTNLPRNPS-amide (amino acids 241–261) conjugated to maleimide-activated keyhole limpet haemocyanin and ovalbumin carrier proteins (Pierce).

Protein-binding assays. GST-XIAP (~3 μg) or GST-CD40 (~6 μg) immobilized on glutathione-Sepharose (5 μl) was added to 50-μl cytosolic extracts (preincubated with or without 1 μM cytochrome *c* and 1 mM dATP for 60 min at 30 °C) or to purified caspases (0.5 μg caspase 3, 6 or 7) in 100 μl caspase assay buffer¹⁶ with 0.1% (w/v) BSA. After incubation at 4 °C for 60 min, beads were removed by centrifugation and washed twice with 100 volumes of 50 mM Tris, pH 7.5, 150 mM KCl, 2 mM DTT, 0.025% Triton-X100 before SDS-PAGE and immunoblot assay.

Transfection of cultured cells. Subconfluent 293T cells were transfected in 6-cm dishes using the calcium phosphate method with 1 μg pcDNA3-human-Bax and either 9 μg control plasmid pcDNA3 or pcDNA3-Myc-XIAP. Transfection efficiency was 80–90% (based on X-gal staining following co-transfection of pCMV-βGal). After culturing for 24 h, both the floating and attached cells were collected and the percentage of dead cells was determined by either trypan-blue or propidium iodide (PI) dye exclusion. Apoptotic cells containing subdiploid DNA were quantified by FACS analysis of PI-stained, ethanol-fixed cells. The remaining cell pellets were lysed in 10 mM HEPES, pH 7.5, 142 mM KCl, 1 mM EGTA, 1 mM DTT, 0.2% NP-40, 0.1 mM PMSF and used for either immunoblot analysis or protease assay.

Received 21 February; accepted 12 May 1996.

- Clem, R. J. & Miller, L. K. Control of programmed cell death by the baculovirus genes p35 and iap. *Mol. Cell. Biol.* **14**, 5212–5222 (1994).
- Roy, N. et al. The gene for neuronal apoptosis inhibitory protein is partially deleted in individuals with spinal muscular atrophy. *Cell* **80**, 167–178 (1995).
- Rothe, M., Pan, M.-G., Henzel, W. J., Ayres, T. M. & Goeddel, D. V. The TNFR2-TRAF signaling complex contains two novel proteins related to baculoviral inhibitor of apoptosis proteins. *Cell* **83**, 1243–1252 (1995).
- Duckett, C. S. et al. A conserved family of cellular genes related to the baculovirus iap gene and encoding apoptosis inhibitors. *EMBO J.* **15**, 2685–2694 (1996).
- Uren, A. G., Pakusch, M., Hawkins, C. J., Puls, K. L. & Vaux, D. L. Cloning and expression of apoptosis inhibitory protein homologs that function to inhibit apoptosis and/or bind tumor necrosis factor receptor-associated factors. *Proc. Natl. Acad. Sci. USA* **93**, 4974–4978 (1996).
- Hay, B. A., Wassarman, D. A. & Rubin, G. M. *Drosophila* homologs of baculovirus inhibitor of apoptosis proteins function to block cell death. *Cell* **83**, 1253–1262 (1995).
- Alnemri, E. S. et al. Human ICE/CED-3 protease nomenclature. *Cell* **87**, 171 (1996).
- Liu, X., Kim, C. N., Yang, J., Jemmerson, R. & Wang, X. Induction of apoptotic program in cell-free

- extracts: requirement for dATP and cytochrome *c*. *Cell* **86**, 147–157 (1996).
9. Kluck, R. M., Bossy-Wetzel, E., Green, D. R. & Newmeyer, D. D. The release of cytochrome *c* from mitochondria: a primary site for Bcl-2 regulation of apoptosis. *Science* **275**, 1132–1136 (1997).
 10. Martin, S. J. & Green, D. R. Protease activation during apoptosis: death by a thousand cuts? *Cell* **82**, 349–352 (1995).
 11. Muzio, M. *et al.* Flice, a novel FADD-homologous ICE/CED-3-like protease, is recruited to the CD95 (Fas/APO-1) death-inducing signaling complex. *Cell* **85**, 817–827 (1996).
 12. Boldin, M. P., Goncharov, T. M., Goltsev, Y. V. & Wallach, D. Involvement of MACH, a novel MORT1/FADD-interacting protease, in Fas/APO-1 and TNF receptor-induced cell death. *Cell* **85**, 803–815 (1996).
 13. Srinivasula, S., Ahmad, M., Fernandes-Alnemri, T., Litwack, G. & Alnemri, E. S. Molecular ordering of the fas-apoptotic pathway: The fas/APO-1 protease Mch5 is a CrmA-inhibitable protease that activates multiple Ced-3/ICE-like cysteine proteases. *Proc. Natl Acad. Sci. USA* **93**, 14486–14491 (1996).
 14. Muzio, M., Salvesen, G. S. & Dixit, V. M. FLICE induced apoptosis in a cell-free system. *J. Biol. Chem.* **272**, 2952–2956 (1997).
 15. Martin, S. J. *et al.* Cell-free reconstitution of Fas-, UV radiation- and ceramide-induced apoptosis. *EMBO J.* **14**, 5191–5200 (1995).
 16. Quan, L. T. *et al.* Proteolytic activation of the cell death protease Yama/CPP32 by granzyme B. *Proc. Natl Acad. Sci. USA* **93**, 1972–1976 (1996).
 17. Zhou, Q. *et al.* Target protease specificity of the viral serpin CrmA: analysis of five caspases. *J. Biol. Chem.* **272**, 7797–7800 (1997).
 18. Bertin, J. *et al.* Apoptotic suppression by baculovirus p35 involves cleavage by and inhibition of a virus-induced CED-3/ICE-like protease. *J. Virol.* **70**, 6251–6259 (1996).
 19. Xiang, J., Chao, D. T. & Korsmeyer, S. J. BAX-induced cell death may not require interleukin 1 β -converting enzyme-like proteases. *Proc. Natl Acad. Sci. USA* **93**, 14559–14563 (1996).
 20. Weil, M. *et al.* Constitutive expression of the machinery for programmed cell death. *J. Cell Biol.* **133**, 1053–1059 (1996).
 21. Kuida, K. *et al.* Altered cytokine export and apoptosis in mice deficient in interleukin-1 β converting enzyme. *Science* **267**, 2000–2003 (1995).
 22. Kuida, K. *et al.* Decreased apoptosis in the brain and premature lethality in CPP32-deficient mice. *Nature* **384**, 368–372 (1996).
 23. Yamakawa, T. *et al.* Increase of solubility of foreign proteins in *Escherichia coli* by coproduction of the bacterial thioredoxin. *J. Biol. Chem.* **270**, 25328–25331 (1995).
 24. Hanada, M., Aimé-Sempé, C., Sato, T. & Reed, J. C. Structure–function analysis of Bcl-2 protein: identification of conserved domains important for homodimerization with Bcl-2 and heterodimerization with Bax. *J. Biol. Chem.* **270**, 11962–11968 (1995).
 25. Sato, T., Irie, S. & Reed, J. C. A novel member of the TRAF family of putative signal transducing proteins binds to the cytosolic domain of CD40. *FEBS Lett.* **358**, 113–118 (1995).
 26. Deveraux, Q., van Nocker, S., Mahaffey, D., Vierstra, R. & Rechsteiner, M. Inhibition of ubiquitin-mediated proteolysis by the *Arabidopsis* 26S protease subunit S5a. *J. Biol. Chem.* **270**, 29660–29663 (1995).
 27. Krajewski, S. *et al.* Immunolocalization of the ICE/Ced-3-family protease, CPP32 (caspase-3), in non-Hodgkin's lymphomas (NHLs), chronic lymphocytic leukemias (CLL), and reactive lymph nodes. *Blood* (in the press).
 28. Orth, K., O'Rourke, K., Salvesen, G. S. & Dixit, V. M. Molecular ordering of apoptotic mammalian CED-3/ICE-like proteases. *J. Biol. Chem.* **271**, 20977–20980 (1996).

Acknowledgements. We thank A. Price and Q. Zhou for technical assistance, N. Roy, M. Ellerby, and L. Ellerby for discussion, N. Thornberry for ICE and V. Dixit for some protease-encoding cDNAs and antibodies.

Correspondence and requests for materials should be addressed to J.C.R. (e-mail: jreed@lcrf.edu).

***Drosophila* Mad binds to DNA and directly mediates activation of *vestigial* by Decapentaplegic**

Jaeseob Kim*, Kirby Johnson†, Hui Ju Chen‡, Sean Carroll*† & Allen Laughon†

* Howard Hughes Medical Institute and Laboratory of Molecular Biology, University of Wisconsin, 1525 Linden Drive, Madison, Wisconsin 53706, USA

† Departments of Genetics and Medical Genetics, 445 Henry Mall, University of Wisconsin-Madison, Madison, Wisconsin 53706, USA

‡ Department of Oncology, McArdle Laboratory, University of Wisconsin-Madison, Madison, Wisconsin 53706, USA

The TGF- β (transforming growth factor- β)-related signalling proteins, including Decapentaplegic (Dpp) in *Drosophila* and bone morphogenic proteins and activin in vertebrates, affect the growth and patterning of a great variety of structures. However, the mechanisms by which these ligands regulate gene expression are not understood. Activation of complexes of type I with type II receptors results in the phosphorylation and nuclear localization of members of the SMAD protein family^{1–9}, which are thought to act as co-activators of transcription, perhaps in conjunction with

sequence-specific cofactors¹⁰. Here we show that the amino-terminal domain of the *Drosophila* Mothers against dpp protein (Mad), a mediator of Dpp signalling^{11–14}, possesses a sequence-specific DNA-binding activity that becomes apparent when carboxy-terminal residues are removed. Mad binds to and is required for the activation of an enhancer within the *vestigial* wing-patterning gene in cells across the entire developing wing blade. Mad also binds to Dpp-response elements in other genes. These results suggest that Dpp signalling regulates gene expression by activating Mad binding to target gene enhancers.

In the *Drosophila* wing imaginal disc, the anteroposterior and dorsoventral compartment boundaries are important signalling sources, and inputs from both axes are required for appendage formation¹⁵. Growth and patterning along the anteroposterior axis depends upon the sequential organizing activities of the Engrailed (En), Hedgehog (Hh) and Decapentaplegic (Dpp) proteins^{16–19}. Dpp acts as a morphogen from its source to organize wing growth and anteroposterior patterning and to activate gene expression over a long range^{19–24}. The *spalt* (*sal*)²⁵ and *optomotor-blind* (*omb*)²⁶ genes are expressed in nested patterns centred on and extending up to 20 cell-diameters away from the stripe of Dpp expression^{22,23} (Fig. 1a). The *vestigial* (*vg*) gene is even more broadly expressed and is required in all cells of the developing wing (Fig. 1a). Activation of *vg* is regulated by signals from both axes through separate *cis*-regulatory elements that control complementary patterns of gene expression²⁴. The 'boundary' enhancer is activated along the dorsoventral boundary through components of the Notch pathway, whereas the 'quadrant' enhancer is activated in the remainder of the developing wing blade (Fig. 1e) by Dpp as well as a signal from the dorsoventral boundary²⁴.

Because Mad is an intracellular signal transducer downstream of Dpp receptors^{1,13,14}, we examined the requirement of Mad activity for *Vg* expression in the wing imaginal disc in mitotic clones with reduced Mad function. Homozygous clones for the strong *Mad*^{1,2} allele in developing wing-blade cells had significantly reduced levels of *Vg* expression and showed a growth disadvantage in comparison with surrounding heterozygous or wild-type cells (twin spot) (Fig. 1b–d, arrows). In contrast, *Mad*^{1,2} clones along the dorsoventral boundary did not show any changes in *Vg* expression levels (Fig. 1b–d, arrowheads). The different effects of the reduction of Mad activity in dorsoventral boundary versus wing-blade clones is explained by the different regulatory elements that control the expression of the *vg* gene in these regions. Mad has no effect on the *Notch*-dependent dorsoventral boundary enhancer, but the quadrant enhancer required Dpp signalling²⁴ and Mad function.

To investigate whether Mad exerts a direct effect on *vg* transcription, we tested whether Mad could bind specifically to the quadrant enhancer. SMAD family members share highly conserved amino- and carboxy-terminal domains, termed MAD homology regions 1 and 2 (MH1 and MH2)², which are separated by a less conserved proline-rich linker region. We found that the Mad MH1 plus linker, expressed as a glutathione S-transferase (GST) fusion protein (designated Mad^N), bound DNA and protected a single interval within the quadrant enhancer in a DNase I footprinting experiment (Fig. 2a); GST and the GST–MAD linker plus MH2 fail to bind DNA (data not shown). The specificity of Mad binding to these protected sequences was demonstrated by a gel mobility-shift assay (Fig. 2b). A 39-base-pair double-stranded oligonucleotide of the *vg* quadrant enhancer containing the Mad-protected region, the Q⁺ probe, was bound readily by Mad^N (Fig. 2b, lane 2). A double-stranded oligonucleotide in which 12 bp of the Mad^N protected region was replaced with two *Bgl*II restriction sites, the Q^m probe, was bound with much lower affinity than the wild-type sequence (Fig. 2b, lane 7). Moreover, the Q^m mutant oligonucleotide did not compete as efficiently as the Q⁺ oligonucleotide with the ³²P-labelled Q⁺ probe (Fig. 2b, compare lanes 3 and 4 with lanes 5 and 6). These data suggest that the binding of Mad^N protein to the quadrant enhancer